Epitalon (Epithalon) — Research Product Overview

**Disclaimer:** This product overview is provided strictly for in-vitro and preclinical research use. [Epitalon](/research/epitalon-telomere) is not approved by the FDA for human use, is not a drug, food, or cosmetic, and nothing in this document constitutes medical advice or a recommendation for human administration. Materials are sold to qualified research professionals for laboratory investigation only.

Overview

Epitalon (also written Epithalon or Epithalone) is a synthetic tetrapeptide identified as the putative active fragment of epithalamin, a bovine pineal gland extract characterized by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Epitalon is one of the most studied "short peptide bioregulators" in the Russian gerontology literature, where it has been investigated for its reported effects on telomerase activity, telomere length, circadian regulation, and lifespan in aged rodents. Most of the primary literature originates from the Khavinson group, with a smaller body of independent replication work conducted elsewhere.

For broader pineal-axis context see our Epithalon and the pineal axis article and the peptides longevity research 2026 overview.

Sequence and Structural Notes

• Amino acid sequence: Ala-Glu-Asp-Gly
• Single-letter code: AEDG
• Molecular formula: C14H22N4O9
• Molecular weight: 390.35 Da
• Length: 4 amino acids (tetrapeptide)
• N-terminus: free amine
• C-terminus: free acid
• Charge at pH 7: approximately -2 (two acidic residues, one neutral, one basic-N-terminus)

Epitalon is a small, highly polar, water-soluble peptide. Its compact size and lack of hydrophobic residues account for its rapid solvation in aqueous buffers and its absence of aggregation issues in storage.

Mechanism of Action (Summary)

1. hTERT transcriptional reactivation — Khavinson et al. reported that Epitalon induces expression of human telomerase reverse transcriptase (hTERT) in cultured human somatic cells that normally maintain hTERT in a transcriptionally repressed state.
2. Telomerase enzymatic activity — measured increases in TRAP-assay activity following Epitalon treatment in human fetal fibroblast cultures.
3. Telomere elongation — reported preservation or lengthening of telomere length and extension of replicative capacity beyond the conventional Hayflick limit in treated cultures.
4. Pineal-axis modulation — reported effects on melatonin synthesis and circadian gene expression in aged rodents, consistent with the peptide's pineal origin.
5. Antioxidant and neuroprotective effects — secondary effects reported in retinal degeneration and oxidative-stress models.

The molecular target of Epitalon at the receptor level has not been definitively identified. Computational and biophysical studies have proposed direct DNA-binding interactions in promoter regions of stress-response genes, but this remains an active area of investigation.

Preclinical Research Summary

The most-cited primary study (Khavinson et al., *Bulletin of Experimental Biology and Medicine*, 2003, PMID 12937682) reported that Epitalon-treated human fetal fibroblast cultures continued dividing past passage 44, while controls senesced at the expected passage 34, with concurrent activation of hTERT and telomerase enzymatic activity. Lifespan studies in aged female rats by the same group reported a 13.3% increase in mean lifespan and reduced spontaneous tumor incidence in Epitalon-treated cohorts. Replication work outside the Khavinson group has been more limited but has generally supported the in-vitro telomerase findings, with a 2025 *Biogerontology* report independently confirming telomere lengthening in human cell lines through telomerase upregulation or alternative-lengthening-of-telomeres (ALT) activity.

Comparator Peptides and Molecules

Epitalon's most distinctive feature is its claimed action on telomerase reactivation, placing it in conceptual contrast to other longevity tool compounds that target metabolism, senescence, or signaling. The closest direct comparators are other short bioregulatory peptides from the Khavinson series — Pinealon (Glu-Asp-Arg, an anti-stress and neuroprotective tripeptide), Vilon (Lys-Glu, a thymic immunomodulator), and Thymalin (a thymic peptide preparation). All share the Khavinson "short peptide bioregulator" framework but differ in target tissue and proposed mechanism. None has reached the level of independent replication characteristic of mainstream pharmacology.

Outside the Khavinson series, the most natural mechanism comparator is TA-65, a small-molecule cycloastragenol-derived telomerase activator marketed for human supplementation. TA-65 has a more controlled commercial pharmacology and several human pilot studies, though its claimed effect sizes are modest. For senescent-cell elimination rather than telomerase preservation, see FOXO4-DRI and the FOXO4-DRI senolytic aging research overview — these address a complementary mechanism (clearance of cells already senescent) rather than prevention of replicative senescence. NAD+ precursors discussed in NAD vs NMN vs NR and the broader sirtuin-NAD axis act on metabolic axes that intersect telomere maintenance through SIRT1 deacetylation of telomere-associated proteins. Researchers stacking longevity tools may also consider GHK-Cu for ECM/dermal effects and the broader mTOR pathway peptides and growth-hormone axis literature.

Deeper Preclinical Breakdown

Khavinson et al. 2003 (*Bull Exp Biol Med*, PMID 12937682) is the single most-cited primary study. Cultured human fetal fibroblasts (the line was not specified in original-language detail beyond "human somatic cells") were treated with Epitalon at 0.05 ng/mL in culture medium across serial passaging. Treated cultures continued dividing past passage 44, while controls senesced at the expected passage 34 (Hayflick limit). Concomitant assays showed elevated hTERT mRNA by qPCR and elevated telomerase activity by TRAP assay. Telomere length was preserved by Southern blot. Limitations include the small reported sample size, the low dose (which raises bioactivity questions and may be in the noise floor of typical peptide assays), and the absence of independent verification within the original paper.

Anisimov, Khavinson, and colleagues published a series of rodent lifespan studies through the early 2000s reporting 13–15% increases in mean lifespan in aged female CBA rats given subcutaneous Epitalon, with associated reduction in spontaneous tumor incidence. Doses were typically 0.1–1 µg/animal weekly. The studies have been criticized for non-standard control practices and limited use of blinded outcome assessment, but the directional findings are consistent with the cellular work. A 2025 *Biogerontology* report (DOI 10.1007/s10522-025-10315-x) provided independent extension, demonstrating telomere lengthening in human cell lines through telomerase upregulation or alternative-lengthening-of-telomeres (ALT) mechanisms — the first thoroughly modern, independent characterization of the proposed mechanism.

The 2025 *Int J Mol Sci* overview (DOI 10.3390/ijms26062691) consolidated Epitalon biology, structural data, and proposed direct DNA binding in promoter regions of stress-response genes. Computational docking studies in this paper proposed binding to the hTERT promoter through interactions with G-quadruplex secondary structures, an attractive but still speculative mechanism. The principal limitation across the Epitalon literature remains the heavy concentration of work in the Khavinson lineage.

Formulation Considerations

Epitalon is supplied as a white lyophilized powder, typically 10 mg, 20 mg, or 50 mg per vial. The compact tetrapeptide is highly water-soluble and reconstitutes rapidly in sterile water or bacteriostatic water for injection with gentle swirling — vortexing is unnecessary. Lyophilized stability is at least 24 months at -20 °C, desiccated and protected from light. Reconstituted stability extends to roughly 30 days at 2–8 °C if kept sterile. The peptide tolerates the pH 5–8 range and is reasonably resistant to freeze-thaw, though aliquoting and freezing at -80 °C remains best practice for long-term work.

Common impurities visible on a quality COA include des-amido variants from Asp deamidation (the most common backbone failure mode), pyroglutamate variants from N-terminal cyclization, truncation fragments, and acetate/TFA counter-ion residue. Researchers should confirm identity by mass spectrometry (M+H]+ at m/z 391.1 within ±0.5 Da) and [HPLC purity at 220 nm. The peptide reconstitution guide, peptide solubility guide, and peptide storage and reconstitution guide cover protocol depth.

Research-Context Dosing Ranges

Cellular: 0.05 ng/mL to 1 µg/mL in fibroblast culture (Khavinson et al. 2003 used 0.05 ng/mL; subsequent independent work has used higher concentrations up to 1 µg/mL). Rodent in-vivo: 0.1–1 µg/animal subcutaneous weekly to twice-weekly, often given seasonally (5-day courses repeated quarterly) in the Khavinson protocols. The unusually low effective concentration in cellular assays is one of the more controversial features of the Epitalon literature; researchers should run dose-response studies extending well above the historical reference doses to confirm robust signal. No human dosing is implied or recommended.

Common Research Applications

• In-vitro hTERT expression assays (qPCR) and TRAP telomerase activity assays
• Replicative-senescence assays in human fetal fibroblasts (IMR90, WI-38, MRC-5)
• Naturally aged rodent lifespan and tumor-incidence studies
• Pineal-axis and circadian gene expression studies
• Comparative work alongside other longevity research compounds — see NAD precursors and the sirtuin-NAD axis

Handling, Reconstitution, and Storage

• Form supplied: white lyophilized powder, typically 10 mg, 20 mg, or 50 mg per vial
• [Reconstitution](/research/peptide-reconstitution-guide): sterile water or bacteriostatic water for injection; the peptide is highly water-soluble and dissolves rapidly with gentle swirling
• Working concentration: 0.5–5 mg/mL typical
• Lyophilized stability: ≥24 months at -20 °C, desiccated and protected from light
• Reconstituted stability: up to 30 days at 2–8 °C; aliquot and freeze at -20 °C or -80 °C for longer-term storage
• pH: stable across pH 5–8; avoid extreme acid or base
• Avoid: repeated freeze-thaw cycles beyond 3–4

See the peptide reconstitution guide for additional protocol guidance.

Lab Specifications

• HPLC purity target: ≥98.0% by RP-HPLC at 220 nm
• Identity confirmation: ESI-MS, observed [M+H]+ at m/z 391.1 within ±0.5 Da of theoretical
• Acetate / TFA content: <10% w/w
• Endotoxin: <1 EU/mg for cell-culture grade
• Water content: <8% by Karl Fischer
• Residual solvents: within ICH Q3C limits

For COA interpretation see how to read a peptide COA and understanding peptide purity.

Cross-References

Related Viking Labs research:

• Epithalon and the pineal axis
• Product overview: FOXO4-DRI
• Product overview: NAD+
• NAD vs NMN vs NR
• Sirtuin-NAD axis
• Peptides longevity research 2026

Summary

Epitalon occupies an unusual position in the longevity-peptide literature: a short, highly conserved tetrapeptide with reported effects on telomerase reactivation, lifespan, and pineal physiology, but with the bulk of the published evidence concentrated in a single research group. Researchers should treat the foundational findings as biologically interesting and worth replicating, design experiments with rigorous controls (vehicle and scrambled-sequence peptide), and verify telomerase and telomere-length endpoints with orthogonal methods (qPCR + TRAP + Southern blot or qFISH).

*This document is provided for research and educational purposes only. Viking Labs does not sell products intended for human consumption.*